Impact of surgery and chemotherapy timing on outcomes in older versus younger epithelial ovarian cancer patients: A nationwide Danish cohort study

Ekmann-Gade, Anne Weng; Schnack, Tine Henrichsen; Seibæk, Lene; Noer, Mette Calundann; Høgdall, Claus

doi:10.1016/j.jgo.2022.08.008

Cited by 4 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from the nationwide Danish cohort study was presented by Anne Weng Ekmann-Gade, aiming to find out differences regarding surgical complexity, chemotherapy management, and treatment delays between older and younger epithelial ovarian cancer patient groups in Denmark 30. In total, 2946 epithelial ovarian cancer patients were included from 2013 to 2018; stratification by age in groups was <70 and ≥ 70 years.…”

Section: Ovarian Cancermentioning

confidence: 99%

Best original research presented at the 23rd European Congress on Gynaecological Oncology—Best of ESGO 2022

Kacperczyk‐Bartnik

Bizzarri

Ángeles

et al. 2022

Int J Gynecol Cancer

View full text Add to dashboard Cite

Best of ESGO 2022 includes a selection of best original research presented during the 23rd European Congress on Gynaecological Oncology between October 27 and 30, 2022 in Berlin. Out of 1107 submitted abstracts, authors of studies which obtained the highest scores in a blinded review process were invited to present their results during four oral sessions, young investigators session, and oral poster sessions. By means of this publication, we aim to provide readers with an overview of the best quality research presented at the European Society of Gynaecological Oncology (ESGO) 2022.

show abstract

Section: Ovarian Cancermentioning

confidence: 99%

Best original research presented at the 23rd European Congress on Gynaecological Oncology—Best of ESGO 2022

Kacperczyk‐Bartnik

Bizzarri

Ángeles

et al. 2022

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…In contrast, for stages III and IV, relative survival at five years was much lower at 36% and 17%, respectively. At ten years, the survival rates were 84%, 59%, 23%, and 8% for stages I, II, III, and IV, respectively [7][8][9].…”

Section: Introductionmentioning

confidence: 98%

Adjuvant Chemotherapy Delay After Primary Debulking Surgery for Advanced Ovarian Cancer at a Teaching Hospital in Southern Nigeria

Alegbeleye O

2023

JGWH

View full text Add to dashboard Cite

Background: Treatment of ovarian cancer involves a combination of surgery with optimal debulking surgery followed by chemotherapy, because many women are diagnosed at an advanced stage. The optimal timing of postoperative chemotherapy for ovarian cancer remains poorly defined. Objectives:To determine the proportion of patient with delayed chemotherapy, the time-to-commencement of adjuvant chemotherapy, and to identify the predictors of delayed chemotherapy among women with advanced ovarian cancer at the University of Port Harcourt Teaching Hospital (UPTH). Material and Methods:This was a prospective cross-sectional study of 57 patients who underwent surgery for advanced ovarian cancer between January 1, 2018, and December 31, 2022. A proforma was used to obtain the socio-demographic and clinical characteristics of the participants. Chemotherapy delay was defined as initiation of multiagent chemotherapy >42 days from primary debulking surgery. Associations of sociodemographic and clinical characteristics with adjuvant chemotherapy delay were evaluated with multivariate logistic regression.Results: Most 20 (35.1%) were aged 45-54 years, with a mean age of 46.9 ± 11.3 years. Majority 37 (64.9%) were married and 31 (54.4%) had tertiary education. The most common histological type was serous 36 (52.6%) followed by mucinous 9 (15.8%). Almost all 55 (96.5%) the women had ascites on presentation, all the women were referred to the study centre, with many 33 (57.9%) of the referrals from private clinics. Many of these patients 46 (84%) had their adjuvant chemotherapy delayed, with 39 (69%) presenting with stage III disease. Financial constraint 35 (51.5%) was the main reason for delayed chemotherapy. Menopause was significantly associated with the delay in adjuvant chemotherapy (chi-square = 7.14, p = 0.01). However, multivariable logistic regression analysis did not identify any potential predictors as a factor for delay in commencing adjuvant chemotherapy. For every unit increase in age of these women, there was an insignificant 12% reduced odds of having delayed adjuvant chemotherapy. Conclusion:Delay in starting adjuvant chemotherapy is known to be a risk factor for overall survival. Being able to identify the causes of these delays will assist healthcare professionals in understanding and mitigating the risk.

show abstract

Impact of FRAilty screening and Geriatric assessment and INtervention in older patients with epithelial Ovarian Cancer: A multicenter randomized clinical trial protocol (FRAGINOC)

Daviu Cobián,

Oreskov,

Blaakaer

et al. 2024

Journal of Geriatric Oncology

View full text Add to dashboard Cite

Impact of surgery and chemotherapy timing on outcomes in older versus younger epithelial ovarian cancer patients: A nationwide Danish cohort study

Cited by 4 publications

References 36 publications

Best original research presented at the 23rd European Congress on Gynaecological Oncology—Best of ESGO 2022

Best original research presented at the 23rd European Congress on Gynaecological Oncology—Best of ESGO 2022

Adjuvant Chemotherapy Delay After Primary Debulking Surgery for Advanced Ovarian Cancer at a Teaching Hospital in Southern Nigeria

Impact of FRAilty screening and Geriatric assessment and INtervention in older patients with epithelial Ovarian Cancer: A multicenter randomized clinical trial protocol (FRAGINOC)

Contact Info

Product

Resources

About